Dermatitis could be suppressed as it develops

November 9, 2012, Medical University of Vienna
Dermatitis could be suppressed as it develops

Excessive immune reactions against the body's own skin cells can lead to painful and even chronic dermatitis. An international team of researchers at the MedUni Vienna, the MedUni Graz and the Salk Institute in California, led by Herbert Strobl, has now unencrypted the mechanism that contributes towards this unwanted autoimmune reaction being suppressed. This may in future lead to common conditions such as chronic allergic dermatitis or psoriasis being halted as they develop and treated.

The generally has two tasks: it needs to be able to respond effectively to viruses and bacteria, and also prevent reactions against the body's own cells. With every inflammation, but also during the natural regeneration process (renewal) of tissue, the body's own cells die. These represent a constant source of inflammation and are therefore eliminated by 'sentry cells' (macrophages and ) which act as the body's own waste disposal system.

These sentry cells are also charged with detecting and, with the help of T-cells in the lymph nodes, with triggering a in the form of inflammation against them. Says Strobl: "The sentry cells therefore carry out a constant balancing act between preventing inflammation caused by the body's own cells and triggering a desired inflammatory response to pathogens from outside the body."

In the study, which has now been published in the highly respected , the researchers from Vienna and Graz, in collaboration with colleagues from California, have been able to demonstrate that the sentry cells are programmed even during their development to detect the body's own , eliminate them and suppress any immune reaction to them.

They have also demonstrated that this mechanism is particularly important for the immune regulation of the skin, as well as the receptor responsible for this. The transmitter substance TGF-beta1 is synthesised in the epidermis and causes the presence of the Axl receptor on the cell surface of Langerhans cells (epidermal sentry cells) as well as on other skin cells. Says Strobl: "If this mechanism is literally switched off, dermatitis and excessive allergic reactions occur."  

Cortisone is currently the most important drug for the treatment of dermatitis – and although it is used effectively for many skin conditions, there is a demand for alternatives. The new findings regarding the mechanisms behind the development of dermatitis could, says Strobl, in future lead to the development of alternative medications that boost the receptor. This work has been financed by the Research Fund for Scientific Research in Austria (FWF).

Explore further: Skin sentry cells promote distinct immune responses

More information: Bauer, T. et al., Identification of Axl as a downstream effector of TGF-β1 during Langerhans cell differentiation and epidermal homeostasis. JEM vol. 209 no. 11 2033-2047. doi: 10.1084/jem.20120493.

Related Stories

Skin sentry cells promote distinct immune responses

July 21, 2011
A new study reveals that just as different soldiers in the field have different jobs, subsets of a type of immune cell that polices the barriers of the body can promote unique and opposite immune responses against the same ...

Immune cell plays dual role in allergic skin disease

October 18, 2011
(Medical Xpress) -- An immune cell involved in initiating the symptoms of an allergic skin reaction may play an equally, or perhaps more important, role in suppressing the reaction once it becomes chronic. This finding in ...

Stopping the itch—new clues into how to treat eczema

October 11, 2012
More than 15% of children suffer with eczema, or atopic dermatitis, an inflammatory skin disease that in some cases can be debilitating and disfiguring. Researchers reporting in the October issue of Immunity have discovered ...

Key mechanism for controlling body's inflammatory response discovered

September 30, 2012
Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can ...

Recommended for you

Improving vaccines for the elderly by blocking inflammation

January 22, 2018
By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.